ArticleLung India : official organ of Indian Chest Society2026
Prognostic factors after pulmonary metastasectomy for colorectal cancer lung metastasis.
Article in Lung India : official organ of Indian Chest Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSurgical resection of lung metastases in patients with colorectal cancer (CRC) can provide long-term survival in selected cases. This study aimed to evaluate the prognostic factors affecting survival after pulmonary metastasectomy (PM) performed for lung metastases due to CRC.
methodsData from 70 patients who underwent PM for CRC-related lung metastases at our center between 2007 and 2021 were retrospectively analyzed. Demographic data, primary tumor characteristics, number, size, and localization of metastases, time to metastasis, and survival data were evaluated.
resultsThe 5-year overall survival (OS) rate was 54.8%, with a median OS of 73 months (95% confidence interval: 50.8-95.1). Factors adversely affecting survival included a history of liver metastasis, short (disease-free interval ≤13 months), left colon primary tumor localization, number of metastases ≥2, and metastasis size >4 cm.
conclusionPM for CRC-related lung metastases can offer a significant survival advantage in selected patients. Specific prognostic factors should be considered when selecting candidates for surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.